Evidence map›Paper›PMID 39261439›Full record

ReviewAdvances in experimental medicine and biology2024

Biomarker-Guided Tailored Therapy in Major Depression.

Giampaolo Perna, Alessandro Spiti, Tatiana Torti, Silvia Daccò, Daniela Caldirola

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Potential value of oral Mogibacterium in major depressive disorder.Frontiers in cellular and infection microbiology · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giampaolo PernaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy. giampaolo.perna@hunimed.eu.
Alessandro SpitiIRCCS Humanitas Research Hospital, Milan, Italy.
Tatiana TortiASIPSE School of Cognitive-Behavioral-Therapy, Milan, Italy.
Silvia DaccòDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Daniela CaldirolaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter provides a comprehensive examination of a broad range of biomarkers used for the diagnosis and prediction of treatment outcomes in major depressive disorder (MDD). Genetic, epigenetic, serum, cerebrospinal fluid (CSF), and neuroimaging biomarkers are analyzed in depth, as well as the integration of new technologies such as digital phenotyping and machine learning. The intricate interplay between biological and psychological elements is emphasized as essential for tailoring MDD management strategies. In addition, the evolving link between psychotherapy and biomarkers is explored to uncover potential associations that shed light on treatment response. This analysis underscores the importance of individualized approaches in the treatment of MDD that integrate advanced biological insights into clinical practice to improve patient outcomes.

Indexed as

BiomarkersMajor Depressive DisorderPrecision MedicineAntidepressive AgentsHumansMachine LearningNeuroimagingPsychotherapyTreatment OutcomeAntidepressive AgentsBiomarkersBiomarkersGeneticsMachine learningMajor depressive disorderNeuroimagingPersonalized medicinePrecision medicine

Identifiers

PMID39261439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.